New Alzheimer’s drug Aducanumab – cost, side effects, timeline and other questions answered
Patients and their families are starting to inquire about the new Alzheimer’s drug approved this week by the US Food and Drug Administration.
Shipments of the medication are expected to go out in just a couple of weeks. Hospitals are on tap to administer treatment when needed. And there is serious division in the FDA, especially around the drug’s effectiveness.
Aducanumab, to be sold under the brand name Aduhelm, was approved to treat patients with Alzheimer’s disease against the recommendation of an FDA advisory committee that concluded last year there is not enough evidence to support approval of the treatment. The FDA has not approved a novel therapy for Alzheimer’s disease since 2003.
New Alzheimer’s drug aducanumab: cost, side effects, timeline and other questions answered
Patients and their families are starting to inquire about the new Alzheimer’s drug approved this week by the US Food and Drug Administration.
Shipments of the medication are expected to go out in just a couple of weeks. Hospitals are on tap to administer treatment when needed. And there is serious division in the FDA, especially around the drug’s effectiveness.
Aducanumab, to be sold under the brand name Aduhelm, was approved to treat patients with Alzheimer’s disease against the recommendation of an FDA advisory committee that concluded last year there is not enough evidence to support approval of the treatment. The FDA has not approved a novel therapy for Alzheimer’s disease since 2003.
As the first Alzheimer s drug approved since 2003, advocates applaud the decision. Critics say the approval was based on inadequate proof that the drug works and balk at the price tag of $56,000 a year.